IP Library Granted Patent US 7,666,584
Granted Patent B2
US 7,666,584 · App. 11/515,475 · Granted Feb 23, 2010

Identification of a pin specific gene and protein (PIN-1) useful as a diagnostic treatment for prostate cancer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,666,584
App. No.
11/515,475
Granted
Feb 23, 2010
Kind
B2
Abstract

The invention relates to nucleic acids encoding a mammalian ABCA5 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, PIN. Further, the invention relates to diagnostic assays for identifying the DNA-binding protein ABCA5 (also known as PIN-1). The invention also relates to oligonucleotide sequence(s) or antibodies that specifically bind with ABCA5 or variants thereof.

Claims (17)

1. A method of diagnosing high grade prostatic intraepithelial neoplasia in a human suspected of having high grade prostatic intraepithelial neoplasia, said method comprising:

a. obtaining a biological sample from said human;

b. determining the level of ATP-binding cassette transporter 5 polypeptide in said biological sample;

c. comparing the level of ATP-binding cassette transporter 5 polypeptide in said biological sample with the level of ATP-binding cassette transporter 5 polypeptide in a biological sample obtained from a like human not afflicted with high grade prostatic intraepithelial neoplasia;

wherein said biological sample is selected from the group consisting of a urine sample and a prostate tissue sample;

wherein said ATP-binding cassette transporter 5 polypeptide comprises the polypeptide of SEQ ID NO: 2; and

wherein when a higher level of ATP-binding cassette transporter 5 polypeptide is determined in said biological sample from said human as compared with the level of ATP-binding cassette transporter 5 polypeptide in said biological sample from said like human, the human is diagnosed with high grade prostatic intraepithelial neoplasia.

2. The method of claim 1 , wherein said determining presence or level of ATP-binding cassette transporter 5 polypeptide in said biological sample is conducted by an assay selected from the group consisting of a DNA binding EMSA assay, ELISA, and Western blot.

3. The method of claim 2 , wherein said assay is performed with an antibody which specifically binds ATP-binding cassette transporter 5 polypeptide.

4. A method of diagnosing high grade prostatic intraepithelial neoplasia in a human suspected of having high grade prostatic intraepithelial neoplasia, said method comprising:

a. obtaining a biological sample from said human;

b. determining the level of ATP-binding cassette transporter 5 mRNA in said biological sample;

c. comparing the level of ATP-binding cassette transporter 5 mRNA in said biological sample with the level of ATP-binding cassette transporter 5 mRNA in a biological sample obtained from a like human not afflicted with high grade prostatic intraepithelial neoplasia;

wherein said biological sample is selected from the group consisting of a urine sample and a prostate tissue sample;

wherein said ATP-binding cassette transporter 5 mRNA comprises a mRNA complementary to the polynucleotide of SEQ ID NO: 1; and

wherein when a higher level of ATP-binding cassette transporter 5 mRNA is determined in said biological sample from said human as compared with the level of ATP-binding cassette transporter 5 mRNA in said biological sample from said like human, the human is diagnosed with high grade prostatic intraepithelial neoplasia.

5. The method of claim 4 , wherein said determining presence or level of ATP-binding cassette transporter 5 mRNA in said biological sample is conducted by an assay selected from the group consisting of a RT-PCR, in situ hybridization and Northern blot.

Assignments (4)
CONFIRMATORY LICENSE Recorded Feb 16, 2022
From: DREXEL UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 059023/0844 →
MERGER Recorded Jan 14, 2015
From: PHILADELPHIA HEALTH & EDUCATION CORPORATION
To: DREXEL UNIVERSITY
Reel/Frame 034764/0236 →
CONFIRMATORY LICENSE Recorded Oct 27, 2011
From: DREXEL UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027129/0928 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2007
From: STEARNS, MARK E; HU, YOUJI; WANG, MIN
To: PHILADELPHIA HEALTH & EDUCATION CORPORATION D/B/A DREXEL UNIVERSITY COLLEGE OF MEDICINE, A 501(C)(3) PENNSYLVANIA NONPROFIT CORPORATION
Reel/Frame 018708/0106 →